Source:http://linkedlifedata.com/resource/pubmed/id/12632023
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
2003-3-12
|
pubmed:abstractText |
The present study investigated the effect of the thrombin inhibitors antithrombin (AT) (with and without unfractionated heparin or low molecular weight heparin), hirudin, inogatran and melagatran on thrombin-thrombomodulin-mediated generation of activated protein C (APC), in solution and on endothelial cells. Sequential incubation with thrombin, thrombin inhibitors and protein C was followed by measurement of APC by an amidolytic assay. The approximate concentrations resulting in 50% inhibition of endothelial cell-mediated APC generation for AT, AT-unfractionated heparin, AT-low molecular weight heparin, hirudin, melagatran and inogatran were 200, 4, 9, 1, 8 and 60 nmol/l, respectively. The normal plasma level of AT is 2800 nmol/l and relevant therapeutic concentrations from clinical trials are 200 nmol/l for hirudin, 500 nmol/l for melagatran and 1000 nmol/l for inogatran. The present study indicates that clinically relevant concentrations of the tested thrombin inhibitors interfere with endothelial-mediated APC generation, which may offer an explanation for the lack of a dose-response effect in clinical trials with thrombin inhibitors.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antithrombins,
http://linkedlifedata.com/resource/pubmed/chemical/Azetidines,
http://linkedlifedata.com/resource/pubmed/chemical/Benzylamines,
http://linkedlifedata.com/resource/pubmed/chemical/Glycine,
http://linkedlifedata.com/resource/pubmed/chemical/Heparin,
http://linkedlifedata.com/resource/pubmed/chemical/Hirudins,
http://linkedlifedata.com/resource/pubmed/chemical/Piperidines,
http://linkedlifedata.com/resource/pubmed/chemical/Protein C,
http://linkedlifedata.com/resource/pubmed/chemical/Thrombin,
http://linkedlifedata.com/resource/pubmed/chemical/Thrombomodulin,
http://linkedlifedata.com/resource/pubmed/chemical/inogatran,
http://linkedlifedata.com/resource/pubmed/chemical/melagatran
|
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
0957-5235
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
14
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
139-46
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:12632023-Antithrombins,
pubmed-meshheading:12632023-Azetidines,
pubmed-meshheading:12632023-Benzylamines,
pubmed-meshheading:12632023-Dose-Response Relationship, Drug,
pubmed-meshheading:12632023-Endothelium, Vascular,
pubmed-meshheading:12632023-Flow Cytometry,
pubmed-meshheading:12632023-Glycine,
pubmed-meshheading:12632023-Heparin,
pubmed-meshheading:12632023-Hirudins,
pubmed-meshheading:12632023-Humans,
pubmed-meshheading:12632023-Piperidines,
pubmed-meshheading:12632023-Protein C,
pubmed-meshheading:12632023-Thrombin,
pubmed-meshheading:12632023-Thrombomodulin
|
pubmed:year |
2003
|
pubmed:articleTitle |
Inhibition of endothelial cell-mediated generation of activated protein C by direct and antithrombin-dependent thrombin inhibitors.
|
pubmed:affiliation |
Department of Cardiology, Karolinska Hospital, Stockholm, Sweden and Department of Surgical Sciences, Karolinska Institutet, Stockholm, Sweden. rikard.linder@medks.ki.se
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|